The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
With new variant gathering pace and what is required, WHO making the right comments and very relevant now Avacta through their latest acquisition have the required volume capicity.
“ COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Through C-TAP, WHO and our partners are committed to making those tools accessible to everyone, everywhere.
Further update on the new variant :
A new highly mutated coronavirus variant has been detected in Switzerland and South Africa, prompting scientists to raise alarm bells over a possible explosion of Covid-19 cases.
The Omicron offshoot, called BA.2.86, carries more than 35 mutations in key portions of the virus compared with XBB.1.5 – the dominant variant through most of 2023.
From the US:
The discovery came as new Covid hospitalisations leaped by 21.6 per cent this week, with an estimated 2,000 Americans requiring specialist care per day, according to figures released by the CDC.
Remember, Avacta moved their LFT production to Belgium where their latest acquisition Coris is based and have excellent LFT production facility.
Significant costs savings for Avacta !!!
Now also able to easily increase production if necessary.
If Covid should return under a new name, Avacta is ready.
With the potential of significant news flow from the company and when you consider the constant news flow from the majors, latest $240 bill Novartis about to be spinning off Sandoz and concentrate on clever medicine such as Precision Oncology, well Avacta is soon to be the hottest company in town and be seriously re-rated.
Meanwhile last hour or so, buy/sell ratio is certainly moving forward and the buyers are quite rightly getting ready for next week with Cohort results/ more noise from the majors and M&A in the hottest area in oncology: Precision Oncology! !